Connect with us

Technology

Arkestro Momentum Drives Leadership Growth and Appoints Industry Powerhouse Veterans

Published

on

Two enterprise SaaS operators bring 50 years of combined experience to Arkestro’s leadership team as Ben Leiken transitions from CTO to become the company’s first Chief Product Officer

SAN FRANCISCO, Aug. 6, 2026 /PRNewswire/ — Arkestro, the leading predictive procurement platform accelerating enterprise scale, today announced the appointments of Tom Aitchison as President and Chief Operating Officer and Ron Rasmussen as Chief Technology Officer.

“Arkestro is entering an exciting new chapter of growth, and building the right leadership team is essential to achieving our vision for predictive procurement,” said Rob DeSantis, CEO and Co-Founder of Arkestro. “Tom’s operational leadership and Ron’s technology expertise will help us scale every part of the business, from operations and customer success to product innovation and engineering, and continue defining the future of predictive procurement.”

Aitchison, who previously served as one of Arkestro’s strategic advisors, has worked alongside the company’s leadership on go-to-market strategy, messaging and the operational systems needed to support its current phase of growth. Across decades of experience scaling enterprise software companies, he has held executive positions at Coupa, Swrve, and Introhive, and helped lead multiple successful acquisitions along with Coupa’s NASDAQ IPO.

“Supply networks keep getting more complex, yet executives want their procurement teams to move faster, uncover more savings, and increase visibility into every buying decision. The pressure isn’t easing, and traditional software can’t keep up,” said Aitchison. “Arkestro is one of the few platforms already built for the reality of the next five years, as procurement becomes the deciding function in how enterprises compete on cost and supply chain resilience. I’m looking forward to helping Arkestro continue scaling, so the teams using this platform become the ones setting the standard the rest of the market has to catch up to.”

Rasmussen joins Arkestro after serving as co-founder and Chief Technology Officer of Latitude 39, an incentive compensation management platform for small and midsize businesses. His career spans more than 25 years of enterprise SaaS technology leadership, with over a decade as CTO of Xactly, a Vista Equity portfolio company, and senior positions at Quova and KnowNow.

Rasmussen will work closely with Ben Leiken, who is stepping into the role of Chief Product Officer. As product and engineering at Arkestro have each grown to require full-time executive focus, the addition of a CPO gives product vision its own dedicated leadership alongside Rasmussen’s engineering execution.

“I’ve spent 25 years building enterprise systems, and this is the first time I’ve seen procurement technology that genuinely changes how a category manager makes buying decisions. Ben and the team have built something truly rare, a predictive intelligence solution that’s actually doing work inside of the platform, not just decorating a dashboard. There’s a lot more we can build on top of that, and it’s why I joined,” said Rasmussen.

This expansion of Arkestro’s leadership comes during a period of significant business momentum for the company. Year to date, total customer spend through Arkestro’s platform has more than tripled compared with the same period last year. As global demand for AI-powered procurement continues rising, Aitchison and Rasmussen will help Arkestro to parallel its growth, scaling business operations and core platform capabilities.

To hear directly from Arkestro’s full leadership team and customers on the future of predictive procurement at scale, register for Optimal ’26, Arkestro’s flagship customer event, taking place October 13–15, 2026 in Houston, TX.

About Arkestro

Arkestro is the leading predictive procurement platform, accelerating enterprise spend transformation and supply chain agility. By combining AI and game theory with Arkestro’s patented three science technologies—Negotiation Science, Supplier Science, and Process Science—Arkestro shifts traditional procurement to become a proactive, results-driven function. Trusted by Fortune 500 companies across industries, Arkestro unlocks trapped savings, optimizes negotiations, and enhances supplier collaboration. Learn more about Arkestro at www.arkestro.com and register for Optimal ’26 Houston, the premier AI event for procurement professionals, taking place October 13–15, 2026.

Media Contact
Cailey Henderson
LaunchSquad
Arkestro@launchsquad.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/arkestro-momentum-drives-leadership-growth-and-appoints-industry-powerhouse-veterans-302844608.html

SOURCE Arkestro

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Etsy to Participate in Upcoming Investor Conference

Published

on

By

BROOKLYN, N.Y., Aug. 6, 2026 /PRNewswire/ — Etsy, Inc. (NYSE: ETSY), which operates two-sided online marketplaces that connect millions of passionate and creative buyers and sellers around the world, today announced that its executives will participate in the Canaccord Genuity 46th Annual Growth Conference in Boston. There will be a webcast fireside chat on August 12, 2026 at 8:00 a.m. ET, which investors can listen to on our investor relations website at investors.etsy.com.

About Etsy

Etsy, Inc. owns and operates the Etsy marketplace, the global destination for unique and creative goods, connecting millions of creative entrepreneurs with buyers around the world. In a time of increasing automation, it’s our mission to keep human connection at the heart of commerce. That’s why we built a place where creativity lives and thrives because it’s powered by people. We help our community of sellers turn their ideas into successful businesses. Our platform connects them with millions of buyers looking for an alternative—something special with a human touch, for those moments in life that deserve imagination.

Etsy was founded in 2005 and is headquartered in Brooklyn, New York.

Etsy has used, and intends to continue using, its Investor Relations website and the Etsy News Blog (etsy.com/news) to disclose material non-public information and to comply with its disclosure obligations under Regulation FD. Accordingly, you should monitor our investor relations website and the Etsy News Blog in addition to following our press releases, SEC filings, and public conference calls and webcasts.

Investor Relations Contact: 
ir@etsy.com
Media Relations Contact:
press@etsy.com

View original content:https://www.prnewswire.com/news-releases/etsy-to-participate-in-upcoming-investor-conference-302843991.html

SOURCE Etsy, Inc.

Continue Reading

Technology

Cryoport Reports Second Quarter 2026 Financial Results

Published

on

By

Second quarter revenue grew 8% year-over-year to $49.0 millionLife Sciences Services revenue increased 15% year-over-yearBioStorage/BioServices revenue grew 25% year-over-year Supporting 779 global clinical trials and 22 commercially approved cell and gene therapies (CGT) as of June 30, 2026

NASHVILLE, Tenn., Aug. 6, 2026 /PRNewswire/ — Cryoport, Inc. (NASDAQ: CYRX) (“Cryoport” or the “Company”), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced financial results for its second quarter (Q2) and first half (H1) of 2026.

Jerrell Shelton, CEO of Cryoport, commented, “Our revenue momentum over the past several periods continued into the second quarter, with total revenue reaching $49.0 million. Life Sciences Services revenue grew 15% year-over-year, led by 25% growth in BioStorage/BioServices revenue. Our Life Sciences Products business also generated solid results during the quarter, driven by continued demand for MVE Biological Solutions’ industry-leading cryogenic systems and the successful introduction of new and innovative products.

“Total revenue from the support of commercial CGT grew 9% year-over-year to $9.4 million. The Life Science Services portion of our revenue from supporting commercial CGT grew 26% year-over-year as the number of patients treated in the community setting and on an outpatient basis continued to ramp. Total revenue for the quarter from supporting CGT clinical trials increased 12% year-over-year to $13.4 million as our customers’ clinical pipelines advanced and further matured. We supported a record 779 clinical trials globally as of June 30, 2026, reflecting the strength of our industry-leading position as the CGT market continues to advance.

“Our second quarter results also reflect meaningful progress on our “pathway to profitability.” Achieving positive adjusted EBITDA in the second quarter represents an important milestone in our ongoing pathway to sustainable profitability and demonstrates the value of our strategic investments and operational initiatives we have executed over the past several years. We are pleased with this accomplishment as we continue to optimize our global operations, leverage our expanding infrastructure, and benefit from the operating leverage that we anticipate will take effect as we increasingly scale and put our investments to work.

“Overall, we delivered a strong second quarter, generating growth across key revenue streams, improving profitability, and achieving an important milestone with positive adjusted EBITDA for the quarter. With our accomplishments to date, we believe that we are well positioned to further expand margins, enhance operating efficiency, and deliver sustainable, profitable long-term growth for our shareholders. We remain focused on executing our strategy, driving financial performance, and capitalizing on the significant opportunities before us. We expect upcoming growth catalysts in our business segments, represented by the expansion of our Global Supply Chain Center Network and recent launches of new products and services, will drive us to new heights in market position, growth, and productivity,” concluded Mr. Shelton.

The following table presents Q2 2026 revenue compared with Q2 2025:

Cryoport, Inc. and Subsidiaries

Revenue 

Three Months Ended
June 30,
(unaudited)

Six Months Ended
June 30,
(unaudited)

(in thousands)

2026

2025

% Change

2026

2025

% Change

Life Sciences Services

$       27,969

$     24,369

15 %

$     54,867

$     47,234

16 %

BioLogistics Solutions

22,359

19,874

13 %

44,027

38,404

15 %

BioStorage/BioServices 

5,610

4,495

25 %

10,840

8,830

23 %

Life Sciences Products

$       21,002

$     21,085

0 %

$     41,902

$     39,260

7 %

Total Revenue

$       48,971

$     45,454

8 %

$     96,769

$     86,494

12 %

BioLogistics Solutions revenue increased 13% year-over-year in Q2 2026, driven by increasing customer activity, continued commercial product development, and clinical advancement within the CGT market. BioStorage/BioServices revenue grew 25% year-over-year, reflecting strong demand for our expanded, integrated services offering, which provides seamless, secure handling of temperature-sensitive materials across our global network.

As of June 30, 2026, the number of commercial cell and gene therapies we support increased to 22 and our total clinical trial count that we support rose to 779 clinical trials worldwide, a net increase of 51 clinical trials over June 30, 2025, with 94 of these clinical trials in Phase 3. The number of trials by phase and region are as follows:

Cryoport Supported Clinical Trials by Phase

Clinical Trials

June 30,

2024

2025

2026

Phase 1

286

304

316

Phase 2

322

342

369

Phase 3

76

82

94

Total

684

728

779

Cryoport Supported Clinical Trials by Region

Clinical Trials

June 30,

2024

2025

2026

Americas

525

556

579

EMEA

114

124

145

APAC

45

48

55

Total

684

728

779

In Q2 2026, four of our customers filed Biologics License Applications (BLA) / Marketing Authorization Applications (MAA). During the Q2 2026, Cryoport’s customer, Orca Bio, received U.S. Food and Drug Administration (FDA) approval for TREGZI™ as the first and only precision-engineered cell therapy for allogeneic stem cell transplant in the treatment of adults with hematological malignancies. Additionally, during Q2 2026, Vertex Pharmaceuticals received supplemental approval from the FDA to expand the label of CASGEVY® for the treatment of patients aged two years and older with either sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs) or transfusion-dependent beta thalassemia (TDT). CASGEVY is the first approved gene therapy indicated for children as young as two years for both SCD and TDT. For the balance of 2026, we anticipate another 11 possible BLA/MAA applications, five possible additional new therapy approvals, and one possible additional approval for label/geographic expansion from our customer base.

Operational milestones

Cryoport Systems’ IntegriCell® cryopreservation services were selected by Verismo Therapeutics, a clinical-stage CAR T-cell therapy company pioneering a novel multi-chain KIR-CAR platform technology for the treatment of solid tumors (SynKIR™-110) and B cell associated disorders and malignancies (SynKIR™-310).Advanced toward the planned launch of BioServices operations at our Global Supply Chain Center in Paris, France, expected in Q4 2026.Continued progress toward the launch of our state-of-the-art Global Supply Chain Center in Santa Ana, California, expected in Q4 2026.Shipped first HE freezers “made in China for China” from our Chengdu, China manufacturing facility.

Financial Highlights

On June 11, 2025, the Company completed the divestiture of its CRYOPDP specialty courier business to DHL Group. The results of CRYOPDP, a former business within Cryoport’s Life Sciences Services segment, are presented as discontinued operations for all periods and are excluded from the non-GAAP financial measures in this release.

Revenue

Total revenue for Q2 2026 was $49.0 million, compared to $45.5 million for Q2 2025, a year-over-year increase of 8%, or $3.5 million. Life Sciences Services revenue for Q2 2026 (representing 57% of our total revenue) was $28.0 million, compared to $24.4 million for Q2 2025, up 15% year-over-year, including BioStorage/BioServices revenue of $5.6 million, up 25% year-over-year. Life Sciences Products revenue for Q2 2026 (representing 43% of our total revenue) was $21.0 million, compared to $21.1 million for Q2 2025.Total revenue for H1 2026 was $96.8 million, compared to $86.5 million for H1 2025. Life Sciences Services revenue for H1 2026 was $54.9 million, compared to $47.2 million for H1 2025, including BioStorage/BioServices revenue of $10.8 million, compared to $8.8 million for H1 2025. Life Sciences Products revenue for H1 2026 was $41.9 million, compared to $39.3 million for H1 2025.

Gross Margin

Total gross margin was 46.6% for Q2 2026, compared to 47.0% for Q2 2025. Gross margin for Life Sciences Services was 49.9% for Q2 2026, compared to 48.9% for Q2 2025. Gross margin for Life Sciences Products was 42.2% for Q2 2026, compared to 44.9% for Q2 2025.Total gross margin was 46.2% for H1 2026, compared to 46.3% for H1 2025. Gross margin for Life Sciences Services was 49.4% for H1 2026, compared to 48.4% for H1 2025. Gross margin for Life Sciences Products was 42.1% for H1 2026, compared to 43.7% for H1 2025.

Operating Costs and Expenses

Operating costs and expenses were $32.9 million for Q2 2026, compared to $31.0 million for Q2 2025. Operating costs and expenses were $64.4 million for H1 2026, compared to $56.9 million for H1 2025.

Loss from Continuing Operations

Loss from continuing operations was $8.3 million for Q2 2026, compared to a loss of $12.0 million for Q2 2025. Loss from continuing operations was $17.7 million for H1 2026, compared to a loss of $18.8 million for H1 2025.

Net Income (Loss) – including Discontinued Operations

Net loss was $8.3 million for Q2 2026, compared to net income of $108.9 million for Q2 2025. Net loss for H1 2026 was $18.8 million, compared to net income of $96.9 million for H1 2025. Net income for Q2 2025 and H1 2025 was primarily driven by the sale of our CRYOPDP specialty courier business during Q2 2025, which contributed $120.9 million and $115.6 million, net of taxes, respectively, to income from discontinued operations.Net loss attributable to common stockholders for Q2 2026 was $10.3 million, or $0.20 per share. Net loss attributable to common stockholders for H1 2026 was $22.8 million, or $0.45 per share. This compares to net income attributable to common stockholders of $106.9 million, or $2.13 per share, and $92.9 million, or $1.85 per share, for Q2 2025 and H1 2025, respectively.

Adjusted EBITDA from Continuing Operations

Adjusted EBITDA from continuing operations was $0.4 million for Q2 2026, compared to a negative $0.9 million for Q2 2025. Adjusted EBITDA from continuing operations for H1 2026 was a negative $0.2 million, compared to a negative $3.7 million for H1 2025.

Cash, Cash equivalents, and Short-Term Investments

Cryoport held $396.7 million in cash, cash equivalents, and short-term investments as of June 30, 2026.

Note: All reconciliations of GAAP to adjusted (non-GAAP) figures above are detailed in the reconciliation tables included later in the press release.

Additional Information

Further information on Cryoport’s financial results is included in the attached condensed consolidated balance sheets and statements of operations, and additional explanations of Cryoport’s financial performance are provided in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, which is expected to be filed with the Securities and Exchange Commission (“SEC”) on August 6, 2026. Additionally, the full report will be available in the SEC Filings section of the Investor Relations section of Cryoport’s website at www.cryoportinc.com.

Earnings Conference Call Information

IMPORTANT INFORMATION: In addition to the earnings release, a document titled “Cryoport Second Quarter 2026 in Review,” providing a review of Cryoport’s business update, will be issued at 4:05 p.m. ET on Thursday, August 6, 2026. The document is designed to be read in advance of the questions and answers conference call and will be accessible at https://ir.cryoportinc.com/news-events/ir-calendar.

Cryoport management will host a conference call at 5:00 p.m. ET on August 6, 2026. The conference call will be in the format of a questions and answers session and will address any queries investors have regarding the Company’s reported results. A slide deck will accompany the call.

Conference Call Information

Date:

Thursday, August 6, 2026

Time:

5:00 p.m. ET

Dial-in numbers:

1-800-717-1738 (U.S.), 1-646-307-1865 (International)

Confirmation code:

Request the “Cryoport Call” or Conference ID: 1142151

Live webcast:

‘Investor Relations’ section at www.cryoportinc.com or click here.

Please allow 10 minutes prior to the call to visit this site to download and install any necessary audio software.

The questions and answers call will be recorded and available approximately three hours after completion of the live event in the Investor Relations section of the Company’s website at www.cryoportinc.com for a limited time. To access the replay of the questions and answers click here. A dial-in replay of the call will also be available to those interested, until August 13, 2026. To access the replay, dial 1-844-512-2921 (United States) or 1-412-317-6671 (International) and enter replay entry code: 1142151#.

About Cryoport, Inc.

Cryoport, Inc. (Nasdaq: CYRX) is a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, with an emphasis on regenerative medicine. We support biopharmaceutical companies, contract manufacturers (CDMOs), contract research organizations (CROs), developers, and researchers with a comprehensive suite of services and products designed to minimize risk and maximize reliability across the temperature-controlled supply chain for the life sciences. Our integrated supply chain platform includes the Cryoportal® Logistics Management Platform, advanced temperature-controlled packaging, informatics, specialized BioLogistics, BioStorage, BioServices, cryopreservation services, and cryogenic systems, which in varying combinations deliver end-to-end solutions that meet the rigorous demands of the life sciences. With innovation, regulatory compliance, and agility at our core, we are “Enabling the Future of Medicine™.” 

Headquartered in Nashville, Tennessee, our company maintains a strong global presence with operations across the Americas, EMEA, and APAC.

For more information, visit www.cryoportinc.com or follow via LinkedIn at https://www.linkedin.com/company/cryoportinc or @cryoport on X, formerly known as Twitter at https://x.com/cryoport for live updates.

Forward-Looking Statements

Statements in this press release which are not purely historical, including statements regarding the Company’s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, those related to the Company’s industry, business, long-term growth prospects, plans, strategies, acquisitions, future financial results and financial condition, such as the Company’s outlook and guidance for full-year 2026 revenue and the related assumptions and factors expected to drive revenue, projected growth trends in the markets in which the Company operates, the Company’s plans and expectations regarding the launch of new products and services, such as the expected timing and benefits of such products and services launches, the Company’s expectations about future benefits of its acquisitions, and anticipated regulatory filings, approvals, label/geographic expansions or moves to earlier lines of treatment approved with respect to the products of the Company’s clients. Forward-looking statements also include those related to the Company’s plans regarding its Global Supply Chain Centers, including expected timing of future openings, the Company’s anticipation that it will benefit from its operating leverage, the Company’s belief that it is well positioned to further expand margins, enhance operating efficiency and deliver sustainable, profitable long-term growth for its shareholders, and the Company’s expectation that upcoming growth catalysts in its business segments will drive the Company to new heights in market position, growth, and productivity. It is important to note that the Company’s actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effects of changing economic and geopolitical conditions, such as those resulting from the war with Iran, supply chain constraints, inflationary pressures, the effects of foreign currency fluctuations, trends in the products markets, variations in the Company’s cash flow, market acceptance risks, the effects of tariffs and other trade restrictions, and technical development risks. The Company’s business could be affected by other factors discussed in the Company’s SEC reports, including in the “Risk Factors” section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC. The forward-looking statements contained in this press release speak only as of the date hereof and the Company cautions investors not to place undue reliance on these forward-looking statements. Except as required by law, the Company disclaims any obligation and does not undertake to update or revise any forward-looking statements in this press release.

Cryoport, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations

Three Months Ended
June 30,
(unaudited)

Six Months Ended
June 30,
(unaudited)

(in thousands, except share and per share data)

2026

2025

2026

2025

Revenue

Life Sciences Services revenue

$                  27,969

$                 24,369

$                  54,867

$                 47,234

Life Sciences Products revenue

21,002

21,085

41,902

39,260

Total revenue

48,971

45,454

96,769

86,494

Cost of revenue:

Cost of services revenue

14,008

12,449

27,755

24,369

Cost of products revenue

12,139

11,628

24,277

22,107

Total cost of revenue

26,147

24,077

52,032

46,476

Gross margin

22,824

21,377

44,737

40,018

Operating costs and expenses:

Selling, general and administrative

28,011

26,908

55,631

48,809

Engineering and development

4,852

4,118

8,759

8,052

Total operating costs and expenses:

32,863

31,026

64,390

56,861

Loss from operations

(10,039)

(9,649)

(19,653)

(16,843)

Other income (expense):

Investment income

3,132

1,466

6,222

3,039

Interest expense

(518)

(618)

(950)

(1,201)

Other expense, net

(325)

(2,939)

(2,693)

(3,239)

Loss before provision for income taxes

(7,750)

(11,740)

(17,074)

(18,244)

Provision for income taxes

(505)

(274)

(613)

(508)

Loss from continuing operations

$                  (8,255)

$                (12,014)

$                (17,687)

$                (18,752)

Income (loss) from discontinued operations, net

120,883

(1,112)

115,640

Net income (loss)

$                  (8,255)

$               108,869

$                (18,799)

$                 96,888

Paid-in-kind dividend on Series C convertible preferred stock

(2,000)

(2,000)

(4,000)

(4,000)

Net income (loss) attributable to common stockholders

$                (10,255)

$               106,869

$                (22,799)

$                 92,888

Net income (loss) per share attributable to common stockholders – basic and diluted

$                    (0.20)

$                     2.13

$                    (0.45)

$                     1.85

Weighted average common shares issued and outstanding – basic and diluted

50,442,796

50,257,112

50,173,730

50,102,918

Gross margin – Total [%]

46.6 %

47.0 %

46.2 %

46.3 %

Gross margin – Services [%]

49.9 %

48.9 %

49.4 %

48.4 %

Gross margin – Products [%]

42.2 %

44.9 %

42.1 %

43.7 %

 

Cryoport, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

June 30,

December 31,

2026

2025

(in thousands)

(unaudited)

Current assets

Cash and cash equivalents

$                    269,267

$                    250,494

Short-term investments

127,426

160,714

Accounts receivable, net

36,454

33,359

Inventories

21,506

23,188

Prepaid expenses and other current assets

5,550

8,419

Total current assets

460,203

476,174

Property and equipment, net

94,516

85,448

Operating lease right-of-use assets

40,323

39,720

Intangible assets, net

135,992

138,082

Goodwill

22,068

22,400

Deposits

2,038

2,092

Deferred tax assets

1,064

1,073

 Total assets 

$                    756,204

$                    764,989

Current liabilities

Accounts payable and other accrued expenses

$                      16,247

$                      15,283

Accrued compensation and related expenses

12,186

12,980

Deferred revenue

1,720

943

Current portion of operating lease liabilities

3,937

4,133

Current portion of finance lease liabilities

448

422

Current portion of convertible senior notes, net

185,687

185,094

Current portion of notes payable

159

163

Current portion of contingent consideration

652

Total current liabilities

221,036

219,018

Notes payable, net

985

1,087

Operating lease liabilities, net

40,076

39,078

Finance lease liabilities, net

726

741

Deferred tax liabilities

1,850

1,354

Other long-term liabilities

832

444

Contingent consideration

629

Total liabilities

265,505

262,351

Total stockholders’ equity

490,699

502,638

Total liabilities and stockholders’ equity

$                    756,204

$                    764,989

Note Regarding Use of Non-GAAP Financial Measures

To supplement our financial statements, which are presented on the basis of U.S. generally accepted accounting principles (GAAP), the following non-GAAP measure of financial performance as defined in Regulation G of the Securities Exchange Act of 1934 is included in this release: adjusted EBITDA from continuing operations. Non-GAAP financial measures are not calculated in accordance with GAAP, are not based on any comprehensive set of accounting rules or principles and may be different from non-GAAP financial measures presented by other companies. Non-GAAP financial measures, including adjusted EBITDA from continuing operations, should not be considered as a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP.

Adjusted EBITDA from continuing operations is defined as loss from continuing operations adjusted for net interest expense, income taxes, depreciation and amortization expense, stock-based compensation expense, acquisition and integration costs, cost reduction initiatives, investment income, unrealized (gain)/loss on investments, foreign currency loss, changes in fair value of contingent consideration and charges or gains resulting from non-recurring events, as applicable.

Management believes that adjusted EBITDA from continuing operations provides a useful measure of Cryoport’s operating results, a meaningful comparison with historical results and with the results of other companies, and insight into Cryoport’s ongoing operating performance. Further, management and the Company’s board of directors utilize adjusted EBITDA from continuing operations to gain a better understanding of Cryoport’s comparative operating performance from period to period and as a basis for planning and forecasting future periods. Adjusted EBITDA from continuing operations is also a significant performance measure used by Cryoport in connection with its incentive compensation programs. Management believes adjusted EBITDA from continuing operations, when read in conjunction with Cryoport’s GAAP financials, is useful to investors because it provides a basis for meaningful period-to-period comparisons of Cryoport’s ongoing operating results, including results of operations, against investor and analyst financial models, helps identify trends in Cryoport’s underlying business and in performing related trend analyses, and it provides a better understanding of how management plans and measures Cryoport’s underlying business.

Cryoport, Inc. and Subsidiaries

Reconciliation of GAAP loss from continuing operations to adjusted EBITDA

(unaudited)

Three Months Ended
June 30,

Six Months Ended
June 30,

2026

2025

2026

2025

(in thousands)

GAAP loss from continuing operations

$          (8,255)

$          (12,014)

$         (17,687)

$         (18,752)

Non-GAAP adjustments to loss:

Depreciation and amortization expense

6,589

6,249

12,991

12,383

Acquisition and integration costs

30

31

Cost reduction initiatives

140

266

140

482

Investment income

(3,132)

(1,466)

(6,222)

(3,039)

Unrealized (gain) loss on investments

(212)

1,082

1,893

1,275

Foreign currency loss

651

2,002

1,105

2,247

Interest expense, net

518

618

950

1,201

Stock-based compensation expense

2,402

2,045

4,797

5,109

Change in fair value of contingent consideration

27

42

(5,178)

Income taxes

505

274

613

508

Other adjustments

1,142

1,142

Adjusted EBITDA from continuing operations

$               375

$               (914)

$               (236)

$           (3,733)

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/cryoport-reports-second-quarter-2026-financial-results-302845362.html

SOURCE Cryoport, Inc.

Continue Reading

Technology

Csquare Reports Record Second Quarter 2026 Results

Published

on

By

Revenue Increased 14.5% Year-Over-Year, Record Bookings of $64.7 Million, Net Loss of $48.8 Million Reflects Pre-IPO Capital Structure, and Adjusted EBITDA Grew 21% to $120.3M

Second Quarter Highlights

Successfully completed the Company’s initial public offering on July 17 and commenced trading on the New York Stock Exchange under the ticker symbol CSQR.Total revenue increased 14.5% year-over-year to $280.4 million, driven by continued strength in the Company’s core colocation business and recurring infrastructure services.Colocation revenue increased 17.5% year-over-year to $210.6 million, reflecting sustained customer demand and deployment activity.Achieved bookings of $64.7 million, a 13th consecutive quarter of record bookings, reflecting strong commercial execution and broad-based demand across all customer profiles.Net loss of $48.8 million, primarily reflecting higher interest expense associated with debt issued prior to IPO reduction in debt levels.Adjusted EBITDA increased 21.0% year-over-year to $120.3 million demonstrating the operating leverage of the Company’s platform.

COPPELL, Texas, Aug. 6, 2026 /PRNewswire/ — Csquare, Inc. (NYSE: CSQR) (“Csquare” or the “Company”), a leading provider of carrier-neutral data center solutions, today reported financial results for the quarter ended June 30, 2026.

“Our second quarter results demonstrate the disciplined execution by our team and the continued strength of Csquare’s platform,” said Spencer Mullee, Chief Executive Officer of Csquare. “We delivered 14.5% revenue growth, achieved a record $64.7 million in bookings, increased Adjusted EBITDA by 21%, and continued to benefit from strong demand for our carrier-neutral digital infrastructure platform.”

“These results reflect the durability of our recurring revenue model, the strength of customer demand across our markets, and the operating leverage inherent in our business as Adjusted EBITDA margin increased 330 basis points to 46.2%. We also reached an important milestone with the successful completion of our initial public offering in July, positioning Csquare with enhanced financial flexibility to support our long-term growth strategy.”

“Demand for high-quality digital infrastructure continues to accelerate as customers expand cloud deployments, AI-enabled workloads, and mission-critical connectivity requirements. We believe our diversified portfolio, disciplined capital allocation strategy, and deep customer relationships position Csquare to capitalize on these long-term secular growth trends while creating sustainable value for shareholders.”

Second Quarter 2026 Results Summary
Revenues
Revenue excluding metered power increased 12.3% to $260.2 million, underscoring the continued strength of the Company’s recurring revenue base and customer expansion activity. 

Second quarter total revenue increased 14.5% year-over-year to $280.4 million, compared to $244.8 million in the prior-year period. Growth was driven by continued demand for the Company’s colocation platform, customer deployments across existing and newly acquired facilities, and expansion of recurring infrastructure services.

Commercial Activity
Commercial momentum remained strong throughout the quarter as Csquare generated record bookings of $64.7 million, exceeding management’s expectations. Quarterly bookings represent the annualized value of new and expansion customer contracts executed during the quarter and serve as a leading indicator of future recurring revenue growth.

Demand was broad-based across enterprise customers, cloud and network providers, and large-scale infrastructure deployments. Management believes the diversity of bookings across customer segments, deployment sizes, workload types, and geographic markets demonstrates the resilience of demand and supports continued long-term growth across the platform. 

Net Loss
Net loss for the second quarter of 2026 was $48.8 million, compared to a net loss of $13.9 million in the second quarter of 2025. The increase was primarily driven by higher interest expense and one-time expenses related to the Company’s initial public offering.

After quarter end, the Company completed its initial public offering and used a significant portion of the proceeds to repay debt, eliminating approximately $63 million of annualized interest expense. As a result, both the elevated interest expense and the one-time IPO-related costs reflected in the second quarter are not indicative of the Company’s expected go-forward earnings profile.

Adjusted EBITDA
Adjusted EBITDA increased 21.0% year-over-year to $120.3 million, compared to $99.4 million in the second quarter of 2025.Adjusted EBITDA margin expanded to 46.2%, compared to 42.9% in the prior-year period, reflecting continued revenue growth, disciplined operating execution, and the inherent operating leverage of the Company’s highly recurring business model.

A reconciliation of Adjusted EBITDA to Net Loss is included in the financial tables accompanying this release. 

Funds From Operations
Funds from Operations for the second quarter of 2026 were $40.8 million, compared to funds from operations of $50.2 million during the second quarter of 2025, representing a 18.9% decline year-over-year. The decrease was primarily the result of an increase in net loss, which was primarily driven by higher interest expense.

A reconciliation of FFO to Net Loss, the most directly comparable GAAP measure, is included in the financial tables accompanying this release.

2026 Guidance Summary

Metric

2026 Outlook

Total Revenue

$1,130 – $1,170 million

Adjusted EBITDA

$460 – $480 million

Recurring Capital Expenditures

$55 – $65 million

Non-Recurring Growth Capital
Expenditures

$610 – $660 million*
* – Includes two new large deals signed at end of Q2

The Company does not provide a reconciliation of forward-looking Adjusted EBITDA because certain items that affect the comparable GAAP measure cannot be reasonably provided without unreasonable effort.

Business Highlights

Generated record bookings of $64.7 million, marking the Company’s 13th consecutive quarter of sequential bookings growth and reflecting sustained demand across enterprise, cloud, and network customers.Expanded contracted power capacity by 44% year-over-year to 410 MW, supported by strategic acquisitions and continued customer deployments. Contracted utilization reached 107%, demonstrating demand that exceeds current sellable capacity and is supported by the Company’s development pipeline and planned capacity expansions.Executed strategic portfolio optimization initiatives through the divestiture of two underperforming leased data centers. As a result, sellable capacity totaled 385 MW as of June 30, 2026, while improving the overall quality and efficiency of the Company’s operating portfolio.Improved customer retention, with quarterly net revenue churn declining to 2.4%, compared to 2.9% in the prior-year period, reflecting continued customer satisfaction and the resilience of the Company’s recurring revenue base.Continued investing in long-term growth, deploying $128 million of growth capital expenditures during the quarter while investing an additional $15 million in recurring capital expenditures to maintain and enhance the Company’s core infrastructure platform.

IPO Highlights
During July 2026, Csquare successfully completed its initial public offering of 50.0 million shares of common stock at a public offering price of $21.00 per share and commenced trading on the New York Stock Exchange under the ticker symbol NYSE: CSQR.

The IPO represents a significant milestone in the Company’s evolution and strengthens its ability to execute its long-term growth strategy. As a public company, Csquare believes it is well positioned to benefit from enhanced access to capital markets, increased visibility among customers and investors, and greater strategic and financial flexibility.

On July 27, 2026, the underwriters exercised their option to purchase an additional 7,499,000 shares at the initial public offering price. The offering generated approximately $1.16 billion in net proceeds, after underwriting discounts and commissions.

The Company used the net proceeds to repay outstanding indebtedness, significantly reducing leverage and strengthening its balance sheet to support future investment opportunities. The debt repayment is expected to reduce the Company’s annual interest expense by approximately $63 million, improving future earnings and cash flow.

Management believes its strengthened capital structure, diversified digital infrastructure platform, and continued investment in capacity expansion position Csquare to capitalize on favorable long-term industry trends and create sustainable value for shareholders. 

Conference Call and Webcast Information
Csquare will host a conference call to discuss its second quarter 2026 results.
Date: August 6, 2026
Time: 5:00pm ET

Webcast: https://app.webinar.net/x07g2Pl2BMQ
A live webcast of the conference call will be available in the Investor Relations section of the Company’s website. A replay of the webcast will be available shortly following the conclusion of the event.

About Csquare
Csquare is a leading North American digital infrastructure platform providing carrier-neutral colocation and interconnection services that support the applications powering the modern economy. The company owns and operates a geographically diverse portfolio of highly engineered data centers across major metropolitan markets in the United States, Canada and the United Kingdom.

Csquare delivers mission-critical infrastructure solutions to a diversified base of enterprise, network, cloud and technology customers. Its facilities provide secure space, resilient power, advanced cooling and dense connectivity ecosystems that enable customers to deploy and operate critical IT infrastructure with confidence.

Through its enterprise-focused approach and interconnection-rich environments, Csquare helps organizations scale efficiently while supporting demanding workloads, including hybrid cloud architectures, latency-sensitive applications and emerging AI-enabled use cases.

Headquartered in Coppell, Texas, Csquare is committed to delivering exceptional reliability, operational excellence and long-term customer partnerships across its portfolio.
For additional information, visit www.Csquare.com.

Key Business Metrics

Q2 2026

Q2 2025

Contracted Power Capacity (MW)

410 MW

285 MW

Sellable Power Capacity (MW)

385 MW

328 MW

Contracted Power Sold (%)

107 %

87 %

Net Revenue Churn (%)

2.4 %

2.9 %

Bookings (Annualized)

$64.7 M

$49.4 M

Non-GAAP Financial Measures
This earnings release contains certain non-GAAP financial measures, including Adjusted EBITDA and FFO. Management believes these measures provide useful supplemental information regarding the Company’s operating performance, cash-generating ability, and underlying business trends. These measures should not be considered as alternatives to financial measures prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). Reconciliations to the most directly comparable GAAP measures are included in the accompanying financial tables.

We prepare our financial statements in conformity with U.S. GAAP, though we believe evaluating our ongoing results of operations may be difficult if limited to reviewing only GAAP financial measures. Accordingly, we use non-GAAP financial measures to supplement our evaluation of our operations.

We believe that these non-GAAP financial measures, when taken collectively with our U.S. GAAP financial statements, may be helpful to investors because they allow for greater transparency into what measures we use in operating our business and measuring our performance and enable comparison of financial trends and results between periods where items may vary independent of business performance. These non-GAAP financial measures are presented for supplemental informational purposes only, should not be considered a substitute for financial information presented in accordance with GAAP, and may be different from similarly titled non-GAAP financial measures used by other companies. Because of these limitations, our non-GAAP financial measures should not be considered in isolation or as substitutes for net (loss) income, or any other measure calculated in accordance with U.S. GAAP, as applicable, and should be considered together with our GAAP financial measures and the reconciliations to the corresponding GAAP financial measures set forth in this press release.

Adjusted EBITDA
We define Adjusted EBITDA as net (loss) income, excluding (i) income taxes, (ii) interest expense, (iii) depreciation and amortization, (iv) gain on lease modification, (v) loss on extinguishment of debt, (vi) bargain purchase gain, (vii) other income (loss), net, and (viii) transaction and other costs. Transaction and other costs consist primarily of acquisition and integration costs, restructuring costs, costs associated with our initial public offering, and employee loan extinguishment expenses directly attributable to specific transactions. The employee loan extinguishment costs are recorded within Selling, marketing, general and administrative expenses in our Condensed Consolidated Statements of Operations. Management uses Adjusted EBITDA as a key measure of our operating performance and to assess the results of our business excluding certain items that we believe are not indicative of our core operating results. In addition, we believe Adjusted EBITDA is frequently used by securities analysts, investors, and other interested parties in the evaluation of data centers and other real estate companies. However, because Adjusted EBITDA is calculated before recurring cash charges, including interest expense and income taxes, which represent significant recurring cash charges necessary to operate our business, and is not adjusted for capital expenditures or other recurring cash requirements of our business, it should not be considered a measure of liquidity or an indicator of our cash flows and its utility as a measure of our performance is limited. Further, Adjusted EBITDA does not reflect our cash requirements or our ability to generate cash to meet those obligations. Other companies may calculate Adjusted EBITDA differently than we do and, as a result, Adjusted EBITDA may not be comparable to other companies’ Adjusted EBITDA. Accordingly, Adjusted EBITDA should not be viewed in isolation or as a substitute for net (loss) income or any other performance measure calculated in accordance with U.S. GAAP. Note: Adjusted EBITDA margin excludes metered power revenue.

Funds from Operations 
Management uses FFO, which is a non-GAAP financial measure commonly used in the real estate industry. This measure is used by management to evaluate performance corresponding to the retail colocation data center industry which has similarities to other real estate type companies. FFO is calculated in accordance with the standards approved by the Board of Governors of the National Association of Real Estate Investment Trusts. FFO represents net (loss) income (calculated in accordance with GAAP), excluding, when applicable (i) loss or gain from the disposition of real estate assets, (ii) depreciation and amortization and (iii) impairment write-downs of real estate assets and investments in entities when the impairment is directly attributable to decreases in the value of depreciable real estate held by the entity.

Management uses FFO as a supplemental performance measure because, in excluding the items identified in the calculation, it provides a performance measure that, when compared year over year, captures trends in utilization rates, pricing and operating costs. In addition, we believe FFO is frequently used by securities analysts, investors, and other interested parties in the evaluation of data centers and other real estate companies. However, because FFO excludes depreciation and amortization and does not capture the changes in the value of our data centers that result from use or market conditions, or the level of capital expenditures necessary to maintain the operating performance of our data centers, all of which have real economic effect and could materially impact our financial condition and results from operations, the utility of FFO as a measure of our performance is limited. Other companies may calculate FFO differently than we do and, as a result, FFO may not be comparable to other companies’ FFO. Accordingly, FFO should not be considered in isolation or as a substitute for net (loss) income or any other performance measure calculated in accordance with U.S. GAAP.

Discussion of Non-GAAP Financial Measures

Three months ended June 30,

(dollars in thousands)

2026

2025

Adjusted EBITDA

$                120,315

$             99,418

FFO

$                40,754

$             50,223

 

Six months ended June 30,

(dollars in thousands)

2026

2025

Adjusted EBITDA

$           228,601

$           185,724

FFO

$             59,299

$             79,041

Adjusted EBITDA increased by $20.9 million, or 21%, to $120.3 million for the three months ended June 30, 2026, compared to $99.4 million for the three months ended June 30, 2025, and increased by $42.9 million, or 23%, to $228.6 million for the six months ended June 30, 2026, compared to $185.7 million for the six months ended June 30, 2025. This increase reflected continued improvement in operating performance across our platform, driven by growth in recurring colocation and interconnection revenues and operating leverage from our cost structure.

Three months ended June 30,

(dollars in thousands)

2026

2025

Net loss

$                     (48,827)

$                     (13,928)

Adjustments:

Interest expense

92,826

51,566

Income tax expense (benefit)

12,231

(2,199)

Depreciation and amortization

89,581

64,151

Other loss (income), net

2,933

(1,929)

Gain on lease modification

(40,043)

Transaction and other costs

11,614

1,757

Adjusted EBITDA

$     120,315

$         99,418

 

Six months ended June 30,

(dollars in thousands)

2026

2025

Net loss

$                (114,780)

$                  (48,843)

Adjustments:

Interest expense

181,189

106,119

Income tax expense (benefit)

482

(7,657)

Depreciation and amortization

174,079

127,884

Loss on extinguishment of debt

5,313

Other loss (income), net

5,551

(1,625)

Gain on lease modification

(40,043)

(51)

Transaction and other costs

22,123

4,584

Adjusted EBITDA

$                   228,601

$                   185,724

FFO decreased by $9.5 million, or 18.9%, to $40.8 million for the three months ended June 30, 2026, compared to $50.2 million for the three months ended June 30, 2025 and decreased by $19.7 million, or 25%, to $59.3 million for the six months ended June 30, 2026, compared to $79.0 million for the six months ended June 30, 2025. This decrease was primarily attributable to an increase in net loss, primarily driven by higher interest expense resulting from the assumption of the 2021 ABS Notes in connection with the 2025 Portfolio Acquisition and interest incurred on additional ABS notes issued during the latter part of 2025. These impacts were partially offset by improved operating performance driven by growth in recurring revenue and a gain on lease modification incurred during the second quarter.

The following table presents the calculation of FFO for the periods presented, with a reconciliation to the most comparable GAAP metric:

For the three months ended June 30,

(dollars in thousands)

2026

2025

Net loss

$              (48,827)

$              (13,928)

Adjustments:

Depreciation and amortization

89,581

64,151

FFO

$               40,754

$               50,223

 

For the six months ended June 30,

(dollars in thousands)

2026

2025

Net loss

$              (114,780)

$              (48,843)

Adjustments:

Depreciation and amortization

174,079

127,884

FFO

$                 59,299

$               79,041

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. federal securities laws. These forward-looking statements include, but are not limited to, statements regarding the Company’s expectations, beliefs, objectives, plans, strategies, future performance, growth opportunities, market demand, trends in bookings, portfolio optimization, AI inference adoption, embedded expansion opportunities, capital allocation strategy, financial position and other statements that are not historical facts. Forward-looking statements may be identified by the use of words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “seek,” “should,” “target,” “will,” “would,” and similar expressions.

Forward-looking statements are based on management’s current expectations and assumptions and are subject to risks, uncertainties and other important factors that could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks and uncertainties include, among others, changes in general economic conditions; our concentration in certain geographic areas; demand for colocation and connectivity services; competition; the availability of utility power, fiber connectivity and other critical infrastructure; customer demand and retention; our customer concentration; the pace and extent of AI adoption; a long sales cycle for our products and services; the Company’s ability to execute its growth strategy and expansion projects; capital market conditions; regulatory developments; cybersecurity incidents; and the other risks described in the Company’s filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” section of the Company’s Registration Statement on Form S-1.

Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Except as required by applicable law, Csquare undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events or otherwise.

Csquare, Inc.

Unaudited Condensed Consolidated Statements of Operations

(in thousands, except per share data)

Three Months
Ended June 30,

Six Months
Ended June 30,

2026

2025

2026

2025

Revenues

$   280,351

$   244,751

$   550,813

$   477,510

Costs and operating expenses:

Cost of revenues, excluding depreciation and
amortization

133,206

122,613

269,660

246,138

Selling, marketing, general and administrative

35,170

22,720

60,892

45,648

Depreciation and amortization

89,581

64,151

174,079

127,884

Gain on lease modification

(40,043)

(40,043)

(51)

Transaction and other costs

3,274

1,757

13,783

4,584

Total costs and operating expenses

221,188

211,241

478,371

424,203

Income from operations

59,163

33,510

72,442

53,307

Interest expense

(92,826)

(51,566)

(181,189)

(106,119)

Loss on extinguishment of debt

(5,313)

Other (loss) income, net

(2,933)

1,929

(5,551)

1,625

Loss before income taxes

(36,596)

(16,127)

(114,298)

(56,500)

Income tax (expense) benefit

(12,231)

2,199

(482)

7,657

Net loss

$   (48,827)

$   (13,928)

$  (114,780)

$   (48,843)

Net loss per share:

Basic and diluted

$       (0.47)

$       (0.13)

$       (1.10)

$       (0.47)

Weighted average common shares outstanding:

Basic and diluted

103,887

103,887

103,887

103,887

 

Csquare, Inc.

Unaudited Condensed Consolidated Balance Sheets

(in thousands)

As of June 30,

As of December 31,

2026

2025

Assets

Current assets:

Cash and cash equivalents

$                  120,843

$                  140,159

Restricted cash

209,517

263,257

Due from related parties

7,768

144,451

Accounts receivable, net

134,711

90,708

Prepaid assets

14,359

7,013

Other current assets

61,143

73,307

Total current assets

548,341

718,895

Property and equipment, net

4,062,607

3,951,089

Right-of-use assets

319,863

355,237

Goodwill

537,233

541,493

Intangible assets, net

404,825

436,299

Other assets

130,445

91,410

Total assets

$                6,003,314

$                 6,094,423

Liabilities and stockholders’/member’s deficit

Current liabilities:

Accounts payable

$                    47,933

$                    34,477

Accrued expenses

123,578

128,606

Due to related parties

3,335

Contract liabilities, current

100,653

96,358

Operating lease liabilities, current

39,566

41,755

Finance lease liabilities, current

13,209

15,020

Total current liabilities

328,274

316,216

Contract liabilities, net of current portion

159,990

122,762

Long-term related party loan

75,000

Long-term debt, net of deferred financing costs

4,890,179

4,755,553

Operating lease liabilities, net of current portion

320,117

391,577

Finance lease liabilities, net of current portion

422,787

428,364

Deferred tax liabilities

154,669

165,600

Other liabilities, non-current

40,915

41,097

Total liabilities

6,391,931

6,221,169

Stockholders’/member’s deficit:

Member’s interest

1,094,620

Common stock

1,039

Additional paid-in capital

1,092,791

Accumulated deficit

(1,469,893)

(1,225,641)

Accumulated other comprehensive (loss) income

(12,554)

4,275

Total stockholders’/member’s deficit

(388,617)

(126,746)

Total liabilities and stockholders’/member’s deficit

$                6,003,314

$                6,094,423

 

Csquare, Inc.

Unaudited Condensed Consolidated Statements of Cash Flows

(in thousands)

Six Months Ended June 30,

2026

2025

Operating activities

Net loss

$       (114,780)

$         (48,843)

Adjustments to reconcile net loss to net cash provided by operating activities:

Depreciation and amortization

174,079

127,884

Amortization of deferred financing costs

24,116

11,837

Employee loan extinguishment

8,340

Loss on extinguishment of debt

5,313

Deferred income tax benefit

(6,562)

(8,167)

Gain on modification of leases

(40,043)

(51)

Unrealized loss on foreign exchange transactions

10,247

Other operating activities

4,103

370

Changes in operating assets and liabilities:

Accounts receivable

(47,309)

(25,144)

Prepaid and other current assets

3,682

(1,736)

Operating lease right-of-use assets

20,708

26,552

Due to (from) related parties

4,161

260

Other assets

(36,669)

(21,771)

Accounts payable and accrued expenses

8,474

(46,343)

Other long-term liabilities

40,012

63,499

Operating lease liabilities

(18,938)

(18,130)

Net cash provided by operating activities

33,621

65,530

Investing activities

Purchase of property and equipment

(277,976)

(113,200)

Related party loans and deposits

127,590

Net cash used in investing activities

(150,386)

(113,200)

Financing activities

Borrowings on long term debt, net of discount

908,204

Repayments on long-term debt

(646,695)

Borrowings on revolving credit facility

112,000

60,000

Repayments on revolving credit facility

(207,900)

Repayment of finance lease liabilities

(6,116)

(8,066))

Distributions to members

(130,528)

Contributions from members

266

732

Borrowings – related party

75,000

Payment of debt financing cost

(443)

(20,847)

Net cash provided by financing activities

50,179

85,428

Effect of foreign currency exchange rates on cash, cash equivalents and
restricted cash

(1,216)

(66)

Cash, cash equivalents and restricted cash

Net change in cash, cash equivalents and restricted cash

$        (67,802)

$           37,692

Balance, beginning of period

403,416

120,587

Balance, end of period

$       335,614

$         158,279

Reconciliation of cash and cash equivalents and restricted cash to the
consolidated balance sheets

Cash and cash equivalents

$       120,843

$           32,296

Restricted cash

209,517

125,983

Long-term restricted cash held within Other Assets

5,254

Total cash and cash equivalents and restricted cash

$       335,614

$         158,279

Supplemental disclosure of cash flow information:

Taxes paid (received)

$           5,016

$               (217)

Interest paid

$       156,597

$           98,576

 

Csquare, Inc.

Disaggregation of Revenues

(in thousands)

Revenues

Three months ended June 30,

(dollars in thousands)

2026

2025

$ Change

% Change

Colocation

$          210,616

$         179,313

$                 31,303

17.5 %

Interconnection

24,661

27,493

(2,832)

(10.3 %)

Other

12,580

12,885

(305)

(2.4 %)

Recurring revenues

247,857

219,691

28,166

12.8 %

Non-recurring revenues

12,345

12,028

317

2.6 %

Metered power revenues

20,149

13,032

7,117

54.6 %

Total revenues

$          280,351

244,751

$                 35,600

14.5 %

 

Six months ended June 30,

(dollars in thousands)

2026

2025

$ Change

% Change

Colocation

$             413,957

$              354,558

$                 59,399

16.8 %

Interconnection

49,614

54,034

(4,420)

(8.2 %)

Other

25,603

22,498

3,105

13.8 %

Recurring revenues

489,174

431,090

58,084

13.5 %

Non-recurring revenues

19,701

21,005

(1,304)

(6.2 %)

Metered power revenues

41,938

25,415

16,523

65.0 %

Total revenues

$             550,813

$              477,510

$                 73,303

15.4 %

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/csquare-reports-record-second-quarter-2026-results-302845374.html

SOURCE Csquare, Inc.

Continue Reading

Trending